Do you recall that a year ago Pharmasset reported a 100% SVR rate for treatment-naive GT2 and 3 hcv patients treated with PSI-7977 and Ribavirin? Here Gilead reports updated results. As quoted below it is 60-64%, not 100%. GT1 treatment-naive patients also scored 84%,not 98% reported earlier.
The SVR24 for all groups will be even lower than these SVR12.
Anemia (low hemoglobin content) is a serious side effect of their triple combo.
[The most common adverse events were headache, fatigue, upper respiratory tract infection and nausea. The most common clinically significant grade 3/4 laboratory abnormality was a hemoglobin reduction.]
Their dual therapy containing Riba is completely useless for GT2 and 3 patients if the treatment time is cut to 8 wks or Riba is cut to 800 mg. The old SOC, Peg/Riba, can cure at the 80% rate. Gilead is camouflaging this weak data with their interim data for their TRIPLE combo, which had a SVR4 of 100% - one dropout. An SVR4 is not SVR24, and the triple's safety profile does not look good for an all-oral.